DNLI
Price
$13.74
Change
+$1.45 (+11.80%)
Updated
Apr 2, 04:59 PM (EDT)
Capitalization
1.78B
41 days until earnings call
NERV
Price
$1.61
Change
+$0.06 (+3.87%)
Updated
Apr 2, 04:59 PM (EDT)
Capitalization
10.84M
41 days until earnings call
Ad is loading...

DNLI vs NERV

Header iconDNLI vs NERV Comparison
Open Charts DNLI vs NERVBanner chart's image
Denali Therapeutics
Price$13.74
Change+$1.45 (+11.80%)
Volume$48.55K
Capitalization1.78B
Minerva Neurosciences
Price$1.61
Change+$0.06 (+3.87%)
VolumeN/A
Capitalization10.84M
DNLI vs NERV Comparison Chart
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. NERV commentary
Apr 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Buy and NERV is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 02, 2025
Stock price -- (DNLI: $12.29 vs. NERV: $1.55)
Brand notoriety: DNLI and NERV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 248% vs. NERV: 169%
Market capitalization -- DNLI: $1.78B vs. NERV: $10.84M
DNLI [@Biotechnology] is valued at $1.78B. NERV’s [@Biotechnology] market capitalization is $10.84M. The market cap for tickers in the [@Biotechnology] industry ranges from $302.51B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileNERV’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • NERV’s FA Score: 0 green, 5 red.
According to our system of comparison, NERV is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 5 TA indicator(s) are bullish while NERV’s TA Score has 3 bullish TA indicator(s).

  • DNLI’s TA Score: 5 bullish, 3 bearish.
  • NERV’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than NERV.

Price Growth

DNLI (@Biotechnology) experienced а -12.96% price change this week, while NERV (@Biotechnology) price change was -16.22% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -5.27%. For the same industry, the average monthly price growth was -7.37%, and the average quarterly price growth was -12.08%.

Reported Earning Dates

DNLI is expected to report earnings on May 13, 2025.

NERV is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-5.27% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($1.79B) has a higher market cap than NERV($10.8M). NERV YTD gains are higher at: -30.235 vs. DNLI (-39.696). NERV has higher annual earnings (EBITDA): 6.02M vs. DNLI (-492.89M). DNLI has more cash in the bank: 832M vs. NERV (21.4M). NERV has less debt than DNLI: NERV (0) vs DNLI (48.7M). DNLI (0) and NERV (0) have equivalent revenues.
DNLINERVDNLI / NERV
Capitalization1.79B10.8M16,528%
EBITDA-492.89M6.02M-8,182%
Gain YTD-39.696-30.235131%
P/E RatioN/A8.95-
Revenue00-
Total Cash832M21.4M3,888%
Total Debt48.7M0-
FUNDAMENTALS RATINGS
DNLI vs NERV: Fundamental Ratings
DNLI
NERV
OUTLOOK RATING
1..100
684
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
57
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
95100
PRICE GROWTH RATING
1..100
9064
P/E GROWTH RATING
1..100
9849
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NERV's Valuation (57) in the Biotechnology industry is somewhat better than the same rating for DNLI (94). This means that NERV’s stock grew somewhat faster than DNLI’s over the last 12 months.

NERV's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DNLI (100). This means that NERV’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (95) in the Biotechnology industry is in the same range as NERV (100). This means that DNLI’s stock grew similarly to NERV’s over the last 12 months.

NERV's Price Growth Rating (64) in the Biotechnology industry is in the same range as DNLI (90). This means that NERV’s stock grew similarly to DNLI’s over the last 12 months.

NERV's P/E Growth Rating (49) in the Biotechnology industry is somewhat better than the same rating for DNLI (98). This means that NERV’s stock grew somewhat faster than DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLINERV
RSI
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
88%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 6 days ago
79%
Bullish Trend 10 days ago
77%
Declines
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
85%
View a ticker or compare two or three
Ad is loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CGC1.020.11
+12.09%
Canopy Growth Corp
L92.090.18
+0.20%
Loews Corp
QDEL34.11-0.86
-2.46%
QuidelOrtho Corp
NAK1.11-0.04
-3.48%
Northern Dynasty Minerals Ltd
CANF1.40-0.08
-5.41%
Can-Fite BioPharma Ltd

NERV and

Correlation & Price change

A.I.dvisor indicates that over the last year, NERV has been loosely correlated with CVAC. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if NERV jumps, then CVAC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NERV
1D Price
Change %
NERV100%
-8.83%
CVAC - NERV
35%
Loosely correlated
-1.81%
SYRE - NERV
35%
Loosely correlated
-5.21%
DNLI - NERV
34%
Loosely correlated
-9.60%
AKRO - NERV
33%
Poorly correlated
-4.55%
ANAB - NERV
30%
Poorly correlated
-1.02%
More